Cue Biopharma (NASDAQ: CUE) reported a first-quarter loss per share (EPS) of $-0.130, missing analysts’ expectations by $0.04. The company’s revenue for the quarter totaled $1.58 million, falling short of the consensus estimate of $1.9 million.
The company’s stock closed at $0.90, marking a decline of 17.43% over the past three months and a significant drop of 50.55% over the last 12 months.
Over the past 90 days, Cue Biopharma received three positive EPS revisions, with no negative revisions. Despite this, the stock has struggled, reflecting investor concerns about its performance.
InvestingPro rates Cue Biopharma’s financial health as “fair performance,” indicating moderate stability and growth potential.
For more details on Cue Biopharma’s earnings and financial status, visit InvestingPro or check out the upcoming earnings reports on Investing.com’s earnings calendar.
Related Topics:
